Off-market insider buying at Theralase Technologies (V:TLT)

Roger John Dumoulin-White, CEO, Director and 10% Holder, acquired 461,282 Common Shares on a direct ownership basis at a price of $0.220 through a prospectus or prospectus exempt offering on November 29th, 2023. The insider also acquired 461,282 Warrants on a direct ownership basis at an exercise price of $0.280 through granting of warrants on November 29th, 2023. This represents a $101,482 investment into the company's shares and an account share holdings change of 4.7%.

Theralase Technologies is in the Advanced Medical Equipment & Technology Sub Industry Group under the Healthcare Sector.

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company's medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.